{"name":"Addrenex Pharmaceuticals, Inc.","slug":"addrenex-pharmaceuticals-inc","ticker":"","exchange":"","domain":"","description":"","hq":"","founded":0,"employees":"","ceo":"","sector":"","stockPrice":0,"stockChange":0,"stockChangePercent":0,"marketCap":"","metrics":{"revenue":0,"revenueGrowth":0,"grossMargin":0,"rdSpend":0,"netIncome":0,"cash":0,"dividendYield":0,"peRatio":0,"fiscalYear":"FY2026"},"revenueBreakdown":[],"timeline":[{"date":"2026-07-28","label":"Q2 2026 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2026-10-28","label":"Q3 2026 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-01-28","label":"Q4 2027 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-04-28","label":"Q1 2027 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-07-28","label":"Q2 2027 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-10-28","label":"Q3 2027 Earnings","type":"earnings","sentiment":"neutral"}],"diseaseAreas":[{"name":"Oncology","slug":"oncology","revenue":0,"percentOfTotal":0,"drugCount":1,"colorKey":"oncology","drugs":[{"name":"ADX415","genericName":"ADX415","slug":"adx415","indication":"Relapsed or refractory acute myeloid leukemia","status":"phase_2"}]},{"name":"Cardiovascular","slug":"cardiovascular","revenue":0,"percentOfTotal":0,"drugCount":1,"colorKey":"immunology","drugs":[{"name":"low dose clonidine HCl sustained release","genericName":"low dose clonidine HCl sustained release","slug":"low-dose-clonidine-hcl-sustained-release","indication":"Hypertension","status":"phase_3"}]}],"pipeline":[{"name":"ADX415","genericName":"ADX415","slug":"adx415","phase":"phase_2","mechanism":"ADX415 is a monoclonal antibody targeting CD47.","indications":["Relapsed or refractory acute myeloid leukemia"],"catalyst":""},{"name":"low dose clonidine HCl sustained release","genericName":"low dose clonidine HCl sustained release","slug":"low-dose-clonidine-hcl-sustained-release","phase":"phase_3","mechanism":"Clonidine HCl works by stimulating alpha-2 adrenergic receptors in the brain, which decreases sympathetic nervous system activity and lowers blood pressure.","indications":["Hypertension"],"catalyst":""}],"recentEvents":[],"realNews":[{"url":"https://news.google.com/rss/articles/CBMic0FVX3lxTE5HcjFCdjNIQlllQVExcTItZE0wUWt3MGtPRTRrdnlDRl8zc1ZWMTBtY2xOUWdTdU9hTy1nOHhHUWpyWEpsWEgwNFBHdmpOVU9FMEFmMVpheXpiMHFiTG16UDlpM1M5di12VXVvMFhmNnFtc0U?oc=5","date":"2024-03-01","type":"pipeline","source":"Straits Research","summary":"Global Narcolepsy Therapeutics Market Size & Analysis Report By 2033 - Straits Research","headline":"Global Narcolepsy Therapeutics Market Size & Analysis Report By 2033","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMiY0FVX3lxTE9aclVLbEtHWW1uRUN5aWg4VVdTMVZCdjJKbmJ2NUp4MGROZnRnN182eW1IYWUySGRzbkw4dzRIa1RjWGNQcktJQVJpc3ZEU1p3dy1PNHViVjdBNHpUbnhWendYVQ?oc=5","date":"2016-08-01","type":"pipeline","source":"Pharma Voice","summary":"What’s New - Pharma Voice","headline":"What’s New","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMi3wFBVV95cUxQZkNmbGw1aUZIM1ZRdEEwaUkySmx1bXZCV3QtLWt6eVV2LTlnQWJmQ3hTalQtT0dnb2pILWdaSlExTHUteExOYko1SWF2ME1udjBBMmhOMWJ4ZUNaTWdwY1c0VXN2Nlk3YUo2aTVkMGxlUWt0RGRSMjJYcUgwR3VFR2Z1eC1oMFZweVVieHdqNDZuRDZ1VDJvZm1VNDZTYThMREhHWkpiNFBQY184UkFwd00xTzNtcHhrWGVrcDgwRXV1d2ttdWlFcmhyR2w4MDNXN1pxX2xoWWlHUkM1RXpR?oc=5","date":"2010-05-07","type":"deal","source":"RTTNews","summary":"Adeona Pharma Partners With Meda To Develop Flupirtine For Treatment Of Fibromyalgia Syndrome - Quick Facts - RTTNews","headline":"Adeona Pharma Partners With Meda To Develop Flupirtine For Treatment Of Fibromyalgia Syndrome - Quick Facts","sentiment":"neutral"}],"patents":[],"drugCount":2,"phaseCounts":{"phase_2":1,"phase_3":1},"enrichmentLevel":0,"visitCount":2,"keyCompetitors":[],"therapeuticFocus":[],"financials":null,"yahoo":null}